vs
MADRIGAL PHARMACEUTICALS, INC.（MDGL）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
MADRIGAL PHARMACEUTICALS, INC.的季度营收约是BRC Group Holdings, Inc.的1.7倍（$321.1M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs -18.2%，领先66.2%），MADRIGAL PHARMACEUTICALS, INC.同比增速更快（210.8% vs -21.9%）
本公司是一家美国生物制药企业，成立于2002年，专注于研发新型合成胆汁酸类似物，可用于治疗原发性胆汁性胆管炎、非酒精性脂肪肝、肝硬化等慢性肝病，以及胆汁酸性腹泻等肠道疾病。
MDGL vs RILY — 直观对比
营收规模更大
MDGL
是对方的1.7倍
$188.3M
营收增速更快
MDGL
高出232.6%
-21.9%
净利率更高
RILY
高出66.2%
-18.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $321.1M | $188.3M |
| 净利润 | $-58.6M | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | -18.6% | 32.3% |
| 净利率 | -18.2% | 47.9% |
| 营收同比 | 210.8% | -21.9% |
| 净利润同比 | 1.4% | 1710.8% |
| 每股收益（稀释后） | $-2.55 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDGLRILY
| Q4 25 | $321.1M | $188.3M | ||
| Q3 25 | $287.3M | $215.3M | ||
| Q2 25 | $212.8M | $188.2M | ||
| Q1 25 | $137.3M | $197.2M | ||
| Q4 24 | $103.3M | $241.0M | ||
| Q3 24 | $62.2M | $225.5M | ||
| Q2 24 | — | $256.0M | ||
| Q1 24 | $0 | $263.4M |
净利润MDGLRILY
| Q4 25 | $-58.6M | $90.3M | ||
| Q3 25 | $-114.2M | $91.1M | ||
| Q2 25 | $-42.3M | $139.5M | ||
| Q1 25 | $-73.2M | $-10.0M | ||
| Q4 24 | $-59.4M | $-5.6M | ||
| Q3 24 | $-107.0M | $-284.4M | ||
| Q2 24 | — | $-433.6M | ||
| Q1 24 | $-147.5M | $-49.2M |
毛利率MDGLRILY
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | 96.7% | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率MDGLRILY
| Q4 25 | -18.6% | 32.3% | ||
| Q3 25 | -39.7% | 30.4% | ||
| Q2 25 | -22.2% | 5.7% | ||
| Q1 25 | -57.8% | -31.2% | ||
| Q4 24 | -64.8% | -69.2% | ||
| Q3 24 | -187.1% | -36.4% | ||
| Q2 24 | — | -90.8% | ||
| Q1 24 | — | -6.1% |
净利率MDGLRILY
| Q4 25 | -18.2% | 47.9% | ||
| Q3 25 | -39.8% | 42.3% | ||
| Q2 25 | -19.9% | 74.1% | ||
| Q1 25 | -53.4% | -5.1% | ||
| Q4 24 | -57.5% | -2.3% | ||
| Q3 24 | -172.0% | -126.1% | ||
| Q2 24 | — | -169.4% | ||
| Q1 24 | — | -18.7% |
每股收益（稀释后）MDGLRILY
| Q4 25 | $-2.55 | $2.78 | ||
| Q3 25 | $-5.08 | $2.91 | ||
| Q2 25 | $-1.90 | $4.50 | ||
| Q1 25 | $-3.32 | $-0.39 | ||
| Q4 24 | $-2.50 | $-0.01 | ||
| Q3 24 | $-4.92 | $-9.39 | ||
| Q2 24 | — | $-14.35 | ||
| Q1 24 | $-7.38 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.7M | $226.6M |
| 总债务越低越好 | $339.9M | $1.4B |
| 股东权益账面价值 | $602.7M | $-171.5M |
| 总资产 | $1.3B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
现金及短期投资MDGLRILY
| Q4 25 | $198.7M | $226.6M | ||
| Q3 25 | $295.7M | $184.2M | ||
| Q2 25 | $186.2M | $267.4M | ||
| Q1 25 | $183.6M | $138.3M | ||
| Q4 24 | $100.0M | $146.9M | ||
| Q3 24 | $232.7M | $159.2M | ||
| Q2 24 | — | $236.9M | ||
| Q1 24 | $622.5M | $190.7M |
总债务MDGLRILY
| Q4 25 | $339.9M | $1.4B | ||
| Q3 25 | $339.8M | $1.3B | ||
| Q2 25 | $118.4M | $1.3B | ||
| Q1 25 | $118.0M | $1.4B | ||
| Q4 24 | $117.6M | $1.5B | ||
| Q3 24 | $117.1M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $116.1M | — |
股东权益MDGLRILY
| Q4 25 | $602.7M | $-171.5M | ||
| Q3 25 | $625.7M | $-260.5M | ||
| Q2 25 | $696.0M | $-351.7M | ||
| Q1 25 | $710.6M | $-496.8M | ||
| Q4 24 | $754.4M | $-488.2M | ||
| Q3 24 | $777.2M | $-497.6M | ||
| Q2 24 | — | $-218.3M | ||
| Q1 24 | $850.8M | $228.4M |
总资产MDGLRILY
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.0B | $1.5B | ||
| Q1 25 | $996.6M | $1.5B | ||
| Q4 24 | $1.0B | $1.8B | ||
| Q3 24 | $1.1B | $2.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | $1.1B | $5.0B |
负债/权益比MDGLRILY
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 0.16× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-133.5M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $-133.8M | — |
| 自由现金流率自由现金流/营收 | -41.7% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MDGLRILY
| Q4 25 | $-133.5M | $26.2M | ||
| Q3 25 | $79.8M | $-60.6M | ||
| Q2 25 | $-47.1M | $-25.6M | ||
| Q1 25 | $-88.9M | $184.0K | ||
| Q4 24 | $-104.5M | $-2.7M | ||
| Q3 24 | $-67.0M | $19.5M | ||
| Q2 24 | — | $111.5M | ||
| Q1 24 | $-149.2M | $135.4M |
自由现金流MDGLRILY
| Q4 25 | $-133.8M | — | ||
| Q3 25 | $79.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-104.7M | — | ||
| Q3 24 | $-67.8M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-149.5M | — |
自由现金流率MDGLRILY
| Q4 25 | -41.7% | — | ||
| Q3 25 | 27.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -101.3% | — | ||
| Q3 24 | -109.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度MDGLRILY
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率MDGLRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDGL
| Rebates Customer Fees Credits Co Pay Assistance And Other | $208.5M | 65% |
| Other | $76.0M | 24% |
| Chargebacks Discounts For Prompt Pay And Other Allowances | $36.6M | 11% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
